Shares of Roivant Sciences Ltd. (ROIV) surged 15.99% during intraday trading on Wednesday, following the release of its fourth-quarter financial results and positive updates on its clinical pipeline.

The biopharmaceutical company reported a significant swing to profitability, with net income attributable to shareholders reaching $302.99 million for the quarter, compared to a loss a year earlier. This unexpected profit was primarily driven by a $770.24 million gain from a litigation settlement with Moderna. The company's income from operations came in at $415.24 million, dramatically beating analyst estimates of a $310.4 million loss.

Beyond the one-time legal gain, investor enthusiasm was fueled by promising early-stage data for the company's experimental drug, IMVT-1402, in patients with difficult-to-treat rheumatoid arthritis. Among 165 evaluable patients, 72.7% showed a clinically meaningful improvement after 16 weeks of treatment. Analysts noted the data was compelling for this refractory patient population.

Roivant also provided a positive business update, reiterating its expectation to launch brepocitinib in dermatomyositis by the end of September 2026 and anticipating key clinical trial data readouts in the second half of the year. The company reported a strong cash position of $4.3 billion, which it stated supports its runway into profitability.